EBE-A22

EBE-A22 (CAS No.: 229476-53-3) is an N-methylated derivative of the quinazoline-based tyrosine kinase inhibitor PD153035, developed as a research tool compound in oncology and signal transduction studies. While PD153035 exhibits high affinity and selectivity for the epidermal growth factor receptor tyrosine kinase (EGFR/ErbB-1) and effectively inhibits receptor phosphorylation, EBE-A22 lacks inhibitory activity against EGFR signaling, rendering it functionally inactive in this pathway. Despite the loss of kinase inhibition, EBE-A22 retains pronounced cytotoxic effects across multiple tumor cell lines, suggesting alternative mechanisms of action that may involve direct interactions with cellular macromolecules such as DNA or other non-kinase targets. This distinctive pharmacological profile makes EBE-A22 a valuable negative control or comparative probe for dissecting EGFR-dependent versus EGFR-independent cytotoxic mechanisms, as well as for studying structure–activity relationships within quinazoline-based inhibitors. In vitro studies typically employ concentrations in the low micromolar range, although exact dosing varies according to experimental design and cellular context, supporting its application in mechanistic assays, cytotoxicity profiling, and drug discovery workflows focused on off-target or noncanonical anticancer activities.